NASDAQ:VYGR
Voyager Therapeutics Stock News
$8.43
-0.200 (-2.32%)
At Close: May 17, 2024
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
02:18pm, Thursday, 05'th May 2022 Zacks Investment Research
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
02:06pm, Thursday, 05'th May 2022 Zacks Investment Research
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
02:00pm, Thursday, 05'th May 2022 Zacks Investment Research
Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
12:03pm, Thursday, 05'th May 2022
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
09:35pm, Wednesday, 04'th May 2022 Zacks Investment Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
06:48pm, Wednesday, 04'th May 2022
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
05:22pm, Wednesday, 04'th May 2022 Zacks Investment Research
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates
03:54pm, Wednesday, 04'th May 2022 Zacks Investment Research
Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
03:04pm, Monday, 02'nd May 2022 Zacks Investment Research
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down
04:29pm, Friday, 29'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
03:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
02:52pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
03:46pm, Monday, 25'th Apr 2022 Zacks Investment Research
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.
Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe
05:19pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
04:08pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
